Other products

Onxeo announces positive DSMB recommendation to continue Livatag® ReLive study in HCC

04/04/201610/03/2019

Paris (France), Copenhagen (Denmark), – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of […]

Onxeo Final Data from Mechanistic Livatag® Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment

04/18/201610/03/2019

Full results presented at AACR Annual Meeting 2016 Support continued evaluation of Livatag® in ongoing Phase III ReLive Trial Paris […]

Onxeo Announces Promising Results from Preclinical Studies of Livatag® in Pancreatic Cancer

11/04/201610/03/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]

Onxeo Announces 9th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC

11/21/201610/03/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]

Onxeo Divests Two Non-Core Products in Oral Pathologies to Vectans Pharma

07/31/201710/03/2019

Transaction confirms Onxeo’s strategic focus on innovative orphan oncology drugs Paris (France), July 31, 2017 – 05:45 pm CEST – […]

Onxeo Grants Exclusive Worldwide License of Validive® developed for the treatment of oral severe mucositis to Monopar Therapeutics

09/13/201710/03/2019

Agreement includes substantial milestone payments up to $108m as well as escalating royalties on future sales Monopar Therapeutics will drive […]

Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag®

09/18/201710/03/2019

Paris (France), September 18, 2017 – 8:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the […]

Onxeo Announces Top-Line Results from ReLive Phase III Study of Livatag® in Advanced Hepatocellular Carcinoma

09/11/201710/03/2019

Paris (France), September 11, 2017 – 8:00 pm CEST– Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), […]

Onxeo Completes Enrollment in Phase III Study of Livatag® for the Treatment of Hepatocellular Carcinoma

01/24/201709/11/2019

Milestone completion in line with expected preliminary outcomes mid-2017 Paris (France), Copenhagen (Denmark), January 24, 2017 – 18:30 CET – […]

Phase II trial results of Validive® presented at the ASCO Conference

04/02/201509/11/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced […]

Validive® at the MASCC/ISOO International Symposium: Oral presentation of Phase II trial results and meeting with its International Advisory Board

06/30/201509/06/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, has presented […]

Positive Phase II preliminary results of Validive® for the prevention of Severe Oral Mucositis in Head and Neck cancer patients

10/30/201409/06/2019

Positive Phase II preliminary results of Validive® For the prevention of Severe Oral Mucositis in Head and Neck cancer patients […]

Onxeo Announces First Outcomes of Livatag® Preclinical Plan

09/12/201609/04/2019

Livatag® Nanoformulation Leads to Increased Exposure and Preferential Affinity for Liver, Supporting Current Relive Phase III Study Rationale Demonstrates Enhanced […]

BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea

04/02/201409/04/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig®

04/01/201409/04/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Onxeo Validive® Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015

10/19/201509/04/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of […]

Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive® for Treatment of Severe Oral Mucositis

10/22/201509/04/2019

Results Presented in Oral ePoster Presentation at ASTRO Annual Meeting 2015 Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, […]

Onxeo Poster Demonstrating Unique Livatag® Mechanism of Action Accepted for Presentation at AACR Annual Meeting

03/16/201609/04/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]

Onxeo announces allowance of U.S. patent for Livatag® in hepatocellular carcinoma

05/10/201709/04/2019

USPTO Notice of Allowance received for patent related to specific route of administration for Livatag® provides protection of related claims […]

Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC

05/23/201709/04/2019

Paris (France), May 23, 2017 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology […]

Onxeo announces positive DSMB recommendation for its Phase III trial with Livatag® in primary liver cancer

11/24/201410/14/2018

Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specializing in the development of orphan oncology drugs, […]

Onxeo reaches second milestone of BPIFrance grant dedicated to Livatag® development as part of NICE Consortium

10/10/201410/14/2018

Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, […]

BioAlliance Pharma announces the launch of Sitavig® in the United States by its partner Innocutis and the granting of a new U.S. Sitavig® patent

07/21/201410/14/2018

BioAlliance Pharma SA (Euronext Paris – BIO), Société d’innovation spécialisée dans le développement de médicaments visant des pathologies orphelines en […]

Execution of a license agreement with EMS for Sitavig® in Brazil

06/25/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

BioAlliance Pharma strengthens Livatag® patent protection in Japan until 2032

06/10/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Livatag® receives Fast Track Designation from the FDA for the treatment of primary liver cancer

05/19/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

BioAlliance Pharma announces major achievements on Validive®: Enrollment completion in the international Phase II trial with Validive® in severe oral mucositis, Presentation of preclinical data at the next ASCO annual meeting

05/05/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

BioAlliance Pharma announces a new positive DSMB recommendation to continue its Phase III clinical trial with Livatag® in primary liver cancer

04/14/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

BioAlliance Pharma collaborates with Penn Pharma on the industrial development of Validive®

03/31/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Sitavig® Licensing Strategy: Execution of licensing agreement with Innocutis for North America and Positive opinion from French and German Health Authorities for Marketing Authorization

03/19/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced major […]

BioAlliance Pharma’s partner, Sosei, announces a partnership with FUJIFILM Pharma for commercialization rights for Loramyc® in Japan

02/04/201410/13/2018

Paris, February 4, 2014 – BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan […]

Strengthening and extension of the industrial protection of Livatag® until 2031 – First delivery of a new European patent

02/18/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced today […]

FDA grants Validive® (clonidine Lauriad®) with a Fast Track Designation for the prevention and treatment of oral mucositis induced by anticancer treatments

01/23/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology, announced today that […]

Onxeo announces positive DSMB recommendation for continuation of Livatag® ReLive study in HCC

10/05/201510/13/2018

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of […]

Onxeo files application for key Livatag® patent

09/15/201510/12/2018

Potential expansion of Livatag IP estate to extend commercial exclusivity through 2036 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an […]

Update on ReLive, Livatag® international phase III clinical trial in HCC – 50% patients randomized

07/21/201510/12/2018

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, updates on […]

Onxeo consolidates its industrial property with a US patent protecting Validive® until 2029

06/18/201510/12/2018

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced […]

Onxeo Announces Final Data from Completed Phase II Trial of Validive® for the Prevention of Severe Oral Mucositis in Head and Neck Cancer Patients

05/26/201510/12/2018

Data confirm Validive® efficacy and safety; Provide basis for planned Phase 3 Trial Full results to be presented at ASCO […]